We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
INSM Stock Slides on CFO Exit, Reiterates '26 Sales View
Read MoreHide Full Article
Key Takeaways
Insmed shares fell nearly 7% after CFO Sara Bonstein announced she will step down on Oct. 30.
Insmed reaffirmed 2026 revenue guidance, including $1.25-$1.40 billion for Brinsupri.
Bonstein's exit follows her nearly seven-year tenure during Insmed's growth and $4.2 billion capital raise.
Shares of Insmed (INSM - Free Report) declined nearly 7% on Monday after the company announced that its chief financial officer (CFO), Sara Bonstein, will step down from her role effective Oct. 30.
The departure came as a surprise to investors, given Bonstein’s nearly seven-year tenure as CFO and her role during a significant period of Insmed’s growth and transformation.
While Insmed did not specify the reason for this transition, it stated that Bonstein’s departure is not related to any disagreement with the company concerning accounting practices, financial statements, internal controls or operations.
Although the leadership change introduces some uncertainty for investors, Insmed reaffirmed its 2026 revenue guidance. This suggests that management has not made any changes to its current financial outlook following the CFO transition.
Why Did INSM Stock Fall on CFO Departure News?
The sharp decline appears to be primarily due to investor uncertainty surrounding the unexpected departure of a long-serving senior executive. Bonstein oversaw Insmed’s finance organization during a period in which the company raised more than $4.2 billion in capital and transitioned into a commercial-stage biotech.
The timing of this departure may have further contributed to the negative reaction. Insmed is entering an important phase of growth, with Brinsupri rapidly scaling and the company targeting cash-flow positivity in 2027. Although Bonstein will remain in her role through the company’s third-quarter 2026 earnings release and conference call on Oct. 29, Insmed has already begun searching for her successor.
Year to date, shares of Insmed have lost 40% against the industry’s 3% growth.
Image Source: Zacks Investment Research
Insmed Reiterates 2026 Revenue Guidance
Despite the CFO transition, the company reaffirmed its full-year 2026 revenue guidance for its marketed products, Arikayce and Brinsupri.
Insmed continues to expect Brinsupri revenues between $1.25 billion and $1.40 billion, while Arikayce sales are in the range of $450-$470 million. Notably, the Brinsupri outlook was raised during its second-quarter results announcement from the previous guidance of at least $1 billion, while the Arikayce guidance remained unchanged.
While Arikayce is approved to treat refractory mycobacterium avium complex (MAC) lung disease in certain adults with limited or no treatment options, Brinsupri is approved for non-cystic fibrosis bronchiectasis (NCFB) in individuals aged 12 years and above.
Over the past 60 days, estimates for AC Immune’s 2026 loss per share have narrowed from 84 cents to 60 cents. Over the same period, earnings estimate for 2027 remained unchanged at 17 cents per share. ACIU shares have lost about 14% year-to-date.
AC Immune’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 33.25%.
Over the past 60 days, estimates for Viking’s 2026 loss per share have narrowed from $4.50 to $4.47, while those for 2027 have narrowed from $4.11 to $4.08. VKTX shares have lost nearly 17% year-to-date.
Viking’s earnings beat estimates in one of the trailing four quarters and missed the mark on the other three occasions, with the average negative surprise being 26.47%.
View the Zacks #1 Rank List
Image: Bigstock
INSM Stock Slides on CFO Exit, Reiterates '26 Sales View
Key Takeaways
Shares of Insmed (INSM - Free Report) declined nearly 7% on Monday after the company announced that its chief financial officer (CFO), Sara Bonstein, will step down from her role effective Oct. 30.
The departure came as a surprise to investors, given Bonstein’s nearly seven-year tenure as CFO and her role during a significant period of Insmed’s growth and transformation.
While Insmed did not specify the reason for this transition, it stated that Bonstein’s departure is not related to any disagreement with the company concerning accounting practices, financial statements, internal controls or operations.
Although the leadership change introduces some uncertainty for investors, Insmed reaffirmed its 2026 revenue guidance. This suggests that management has not made any changes to its current financial outlook following the CFO transition.
Why Did INSM Stock Fall on CFO Departure News?
The sharp decline appears to be primarily due to investor uncertainty surrounding the unexpected departure of a long-serving senior executive. Bonstein oversaw Insmed’s finance organization during a period in which the company raised more than $4.2 billion in capital and transitioned into a commercial-stage biotech.
The timing of this departure may have further contributed to the negative reaction. Insmed is entering an important phase of growth, with Brinsupri rapidly scaling and the company targeting cash-flow positivity in 2027. Although Bonstein will remain in her role through the company’s third-quarter 2026 earnings release and conference call on Oct. 29, Insmed has already begun searching for her successor.
Year to date, shares of Insmed have lost 40% against the industry’s 3% growth.
Image Source: Zacks Investment Research
Insmed Reiterates 2026 Revenue Guidance
Despite the CFO transition, the company reaffirmed its full-year 2026 revenue guidance for its marketed products, Arikayce and Brinsupri.
Insmed continues to expect Brinsupri revenues between $1.25 billion and $1.40 billion, while Arikayce sales are in the range of $450-$470 million. Notably, the Brinsupri outlook was raised during its second-quarter results announcement from the previous guidance of at least $1 billion, while the Arikayce guidance remained unchanged.
While Arikayce is approved to treat refractory mycobacterium avium complex (MAC) lung disease in certain adults with limited or no treatment options, Brinsupri is approved for non-cystic fibrosis bronchiectasis (NCFB) in individuals aged 12 years and above.
INSM’s Zacks Rank
Insmed currently carries a Zacks Rank #3 (Hold).
Insmed, Inc. Price
Insmed, Inc. price | Insmed, Inc. Quote
Our Key Picks Among Biotech Stocks
Some better-ranked stocks in the sector include AC Immune (ACIU - Free Report) and Viking Therapeutics (VKTX - Free Report) , each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Over the past 60 days, estimates for AC Immune’s 2026 loss per share have narrowed from 84 cents to 60 cents. Over the same period, earnings estimate for 2027 remained unchanged at 17 cents per share. ACIU shares have lost about 14% year-to-date.
AC Immune’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 33.25%.
Over the past 60 days, estimates for Viking’s 2026 loss per share have narrowed from $4.50 to $4.47, while those for 2027 have narrowed from $4.11 to $4.08. VKTX shares have lost nearly 17% year-to-date.
Viking’s earnings beat estimates in one of the trailing four quarters and missed the mark on the other three occasions, with the average negative surprise being 26.47%.